文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

低收入国家接受蛋白酶抑制剂单药二线治疗失败的人类免疫缺陷病毒1型感染者蛋白酶抑制剂耐药演变:EARNEST随机试验中的观察性分析

Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial.
PubMed 文献 · Clin Infect Dis · 2019-01-01

在低收入国家,HIV治疗项目中病毒载量检测有限常延迟发现治疗失败。本研究回顾性检测EARNEST试验中386例随机接受洛匹那韦单药治疗(先经雷特格韦诱导)患者的2164份保存血浆样本,发现治疗失败后继续单药治疗者多在1年内出现中/高水平洛匹那韦耐药,但仍对达芦那韦敏感。

要点

  • 失败时20%患者对洛匹那韦中/高水平耐药,失败后40-48周升至68%。
  • 失败后40-48周51%对阿扎那韦中/高水平耐药,17%对达芦那韦 intermediate 水平耐药、无高水平耐药。
  • 平均每年产生1.7个PI突变(95%CI 1.5-2.0),病毒载量上升缓慢,由不依从和PI突变驱动。

核心结论

  • 多数患者在单药治疗下持续病毒复制1年内出现中/高水平洛匹那韦耐药,但仍对达芦那韦保持敏感。
  • 治疗失败后病毒载量缓慢上升,由不依从和PI突变发展驱动。

研究设计与样本

  • EARNEST随机试验内的观察性分析,回顾性检测386例随机接受洛匹那韦单药治疗(先经雷特格韦诱导)患者的2164份保存血浆样本。
  • 病毒载量>1000 copies/mL时进行蛋白酶基因型耐药检测,评估从病毒学失败(确认VL>1000 copies/mL)至停用PI单药期间的PI耐药突变演变,采用混合效应模型分析关联。

主要发现

  • 118例失败后中位随访68周(IQR 48-88周)。
  • 失败时20%对洛匹那韦中/高水平耐药;失败后40-48周,68%对洛匹那韦、51%对阿扎那韦中/高水平耐药,17%对达芦那韦中水平耐药(无高水平)。
  • 常见PI突变为M46I、I54V和V82A;平均每年产生1.7个PI突变(95%CI 1.5-2.0),首个突变后增加、后续突变后减少(P < .0001)。
  • 病毒载量变化幅度小,主要由不依从(P = .006)和PI突变发展(P = .0002)驱动;I47A与病毒载量上升幅度大于其他突变相关(P = .05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited viral load (VL) testing in human immunodeficiency virus (HIV) treatment programs in low-income countries often delays detection of treatment failure. The impact of remaining on failing protease inhibitor (PI)-containing regimens is unclear. METHODS: We retrospectively tested VL in 2164 stored plasma samples from 386 patients randomized to receive lopinavir monotherapy (after initial raltegravir induction) in the Europe-Africa Research Network for Evaluation of Second-line Therapy (EARNEST) trial. Protease genotypic resistance testing was performed when VL >1000 copies/mL. We assessed evolution of PI resistance mutations from virological failure (confirmed VL >1000 copies/mL) until PI monotherapy discontinuation and examined associations using mixed-effects models. RESULTS: Median post-failure follow-up (in 118 patients) was 68 (interquartile range, 48-88) weeks. At failure, 20% had intermediate/high-level resistance to lopinavir. At 40-48 weeks post-failure, 68% and 51% had intermediate/high-level resistance to lopinavir and atazanavir; 17% had intermediate-level resistance (none high) to darunavir. Common PI mutations were M46I, I54V, and V82A. On average, 1.7 (95% confidence interval 1.5-2.0) PI mutations developed per year; increasing after the first mutation; decreasing with subsequent mutations (P < .0001). VL changes were modest, mainly driven by nonadherence (P = .006) and PI mutation development (P = .0002); I47A was associated with a larger increase in VL than other mutations (P = .05). CONCLUSIONS: Most patients develop intermediate/high-level lopinavir resistance within 1 year of ongoing viral replication on monotherapy but retain susceptibility to darunavir. Viral load increased slowly after failure, driven by non-adherence and PI mutation development. CLINICAL TRIALS REGISTRATION: NCT00988039.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Thompson JA, Kityo C, Dunn D, et al. Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial. Clin Infect Dis. 2019. PMID: 30060027. doi:10.1093/cid/ciy589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。